The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis.

Clin Appl Thromb Hemost · 2021 · PMC7930650 · PMID 33651658

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

likely to be significantno p-value reported

They claimed that this is likely to be due to the small sample size and that the results are likely to be significant once more data on rivaroxaban in CAT are made available. 8 Our review, with excellent power, confirmed their findings.

also in 1,824 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.